Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to methods of treating an auditory disorder. In particular, the present invention relates to treating an auditory disorder using supraparticles comprising a therapeutic payload.
Core Innovation
The invention provides a method of treating an auditory disorder in a human subject by administering, to the subject's middle ear cavity or inner ear, a supraparticle comprising a therapeutic payload. The therapeutic payload is a neurotrophic factor, and spiral ganglion neuron (SGN) survival is observed across a wide extent of the cochlea. The auditory disorder is noise induced hearing loss, and the approach is directed to supporting SGN survival in the cochlea after noise-induced damage.
The supraparticle-mediated delivery uses pore-network supraparticles loaded with therapeutic payloads, in which neurotrophic factors are emphasized as therapeutic payloads. The document further supports payload diversity, including combinations in which a neurotrophic factor is provided together with other agents, and multi-payload supraparticles. The therapeutic payload is delivered into the middle ear cavity or inner ear to enable distribution across a wide extent of the cochlea.
The invention is also characterized by supraparticles configured for delivery into the ear, including administration to specific cochlear entry sites such as round window, oval window, and cochlear implantation-related sites. The document describes a sustained presence of the delivered payload consistent with clearance over about one week, alongside biocompatibility/safety observations in cochlear tissue. Functional support is reported as enhanced SGN survival across the cochlea and recovery of synapse/ribbon synapse numbers after noise-induced damage.
Claims Coverage
The independent claim covers a supraparticle-delivered neurotrophic factor treatment for noise induced hearing loss, requiring SGN survival across a wide extent of the cochlea when administered to the middle ear cavity or inner ear. The dependent claims further specify the neurotrophic factor selection, payload amount constraints, delivery site refinements, multi-supraparticle administration, and combination payloads.
Supraparticle neurotrophic factor delivery to middle ear cavity or inner ear
Administering, to the subject's middle ear cavity or inner ear, a supraparticle comprising a therapeutic payload, wherein the therapeutic payload is a neurotrophic factor.
SGN survival across a wide extent of the cochlea for noise induced hearing loss
Observing spiral ganglion neuron (SGN) survival across a wide extent of the cochlea, wherein the auditory disorder is noise induced hearing loss.
Neurotrophic factor selected from enumerated set
The neurotrophic factor is selected from BDNF, nerve growth factor, neurotrophin-3, neurotrophin-4, CNTF, GDNF, or IL-11.
Neurotrophin amount within a specified range
The supraparticle comprises between 1.5 μg and 15 μg of neurotrophin.
Round window or oval window administration
Administer the supraparticle onto the subject's round window or oval window.
At least two supraparticles per ear
Administer at least two supraparticles to an ear of the subject.
Neurotrophic factor together with a steroid or an antibiotic
The supraparticle comprises BDNF together with a steroid or an antibiotic.
Overall, claim coverage centers on administering a supraparticle containing a neurotrophic factor into the middle ear cavity or inner ear for noise induced hearing loss with observed SGN survival across a wide extent of the cochlea. Dependent claim refinements constrain the neurotrophic factor to an enumerated list, impose a neurotrophin amount range, specify administration to round or oval window, require multiple supraparticles for an ear, and allow combination payloads including BDNF with a steroid or an antibiotic.
Stated Advantages
Improved spiral ganglion neuron (SGN) survival observed across a wide extent of the cochlea.
Supports functional recovery associated with enhanced SGN survival after noise-induced damage, including recovery of synapse/ribbon synapse numbers.
Wide cochlear distribution of delivered labeled neurotrophin is reported.
Sustained release and/or clearance behavior over about one week is reported.
Biocompatibility/safety in cochlear tissue is reported, with limited fibrosis/new bone near an implantation site.
Documented Applications
Treating noise induced hearing loss in a human subject by administering a neurotrophic factor-loaded supraparticle into the middle ear cavity or inner ear with SGN survival across a wide extent of the cochlea.
Treating or preventing auditory disorders in the ear using pore-network supraparticles loaded with therapeutic payloads including neurotrophic factors and combinations with other agents, including routes such as round window, oval window, and cochlear implantation-related sites.
Interested in licensing this patent?